<DOC>
	<DOCNO>NCT02423200</DOCNO>
	<brief_summary>This study assess effect VX-745 marker disease central nervous system patient MCI due AD mild AD . The study also evaluate safety tolerability VX-745 patient 6 week dosing , well plasma cerebrospinal fluid concentration VX-745 dosing .</brief_summary>
	<brief_title>Clinical Pharmacology p38 MAP Kinase Inhibitor , VX-745 , Mild Cognitive Impairment Due Alzheimer 's Disease ( AD ) Mild AD</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Age 60 85 ( inclusive ) Willing able provide inform consent Clinical presentation consistent MCI due AD mild AD Gradual progressive decline memory function &gt; 6 month Amnestic presentation neuropsychological test rapid forgetting ( % reduction 1.5 standard deviation mean ) Clinical Dementia Rating ( CDR ) Sum Box ( SOB ) score â‰¥0.5 MiniMental State Examination ( MMSE ) range : 20 30 Brain hypometabolism 18F2fluoro2deoxyglucose ( FDG ) PET Participants may take medication AD , provide dose medication stable &gt; 3 month . Evidence neurodegenerative disease AD Inability reason undergo MRI scan ( e.g . pacemaker , vascular stent stent graft ) . Patients require sedation screening procedure MRI may receive shortacting sedative . Psychiatric disorder would compromise ability comply study requirement History cancer within last 5 year , except basal cell carcinoma , nonsquamous skin carcinoma , prostate cancer carcinoma situ significant progression past 2 year Significant cardiovascular , pulmonary , renal , liver , infectious disease , immune disorder metabolic/endocrine disorder disease would preclude treatment p38 MAP kinase inhibitor and/or assessment drug safety efficacy Recent ( &lt; 90 day ) change AD medication prescribe cognitive reason potential impact cognition Psychotropic drug take within 1 month . Anticoagulant drug take within 1 week . Participation study investigational drug le 6 month 5 halflives investigational drug , whichever longer , enrollment study Male subject female partner childbearing potential unwilling unable adhere contraception requirement Female subject reach menopause hysterectomy bilateral oophorectomy/salpingoophorectomy Positive urine serum pregnancy test plan desire become pregnant course trial Donation &gt; 500 mL blood blood product within 2 month History alcohol and/or illicit drug abuse within 6 month . Infection hepatitis A , B C HIV . Any factor deem investigator likely interfere study conduction</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>